Local Surgical Treatment of Hepatic Metastases from Colorectal Carcinoma: Survival Times and Sites of Recurrence
This chapter summarizes the experience at Roswell Park Memorial Institute with resectable liver metastases and with hepatic artery ligation for unresectable metastases from colorectal carcinoma. Survival times and patterns of recurrence were noted in 36 patients with documented colorectal adenocarcinoma metastatic to the liver who underwent resection. The overall median survival time following liver resection was 22 months. Survival was not influenced by the type of surgical resection performed. Survival time following resection of solitary lesions was 28 months and following resection of multiple lesions, 21 months. The difference between survival times of patients with synchronous metastases (25 months) and patients with metachronous metastases (16 months) from the time of liver resection was not statistically significant. Patterns of recurrence revealed that 11 of 17 patients experienced recurrences in the liver and in extrahepatic sites. Only two patients died with recurrent metastasis only in the liver.
From April 1975 to January 1982, 97 patients underwent hepatic artery ligation for biopsyroven metastatic adenocarcinoma of the colon and rectum. All patients undergoing ligation had 50% or more of their liver involved with metastases. The overall median survival time was 10 months. The survival rate was determined in relation to performance status, preoperative alkaline phosphatase and total bilirubin levels, and the presence of extrahepatic intra abdominal disease. We cannot conclude that hepatic artery ligation is an effective means of treating unresectable liver metastases from this retrospective study. What can be concluded is that important patient stratifications in predicting survival time must be taken into consideration for evaluating any form of treatment for unresectable liver metastases. The median survival time for patients with 0–1 performance status was 12 months. Patients with preoperative alkaline phosphatase levels less than two times normal also had a median survival time of 12 months. For patients with total bilirubin levels of less than two times normal the median survival time was four months.
KeywordsLiver Metastasis Liver Resection Hepatic Resection Median Survival Time Hepatic Metastasis
Unable to display preview. Download preview PDF.
- 1.Silverberg E: Cancer Statistics, 1985. CA 35: 19–35, 1985.Google Scholar
- 3.Foster JH, Berman MM: Solid liver tumors. WB Saunders, Philadelphia, 1977.Google Scholar
- 8.Sparks FC, Mosher MB, Wolfgang G, Hallaver WC, Silverstein M3, Rangel D, Passaro E Jr, Morton DL: Hepatic artery ligation and postoperative chemotherapy for hepatic metastases: Clinical and pathologic results. Cancer 35: 1074–1082, 1975.Google Scholar
- 12.Grage TB, Vassilopoules PP, Shingleton WW, Jubert AV, Elias EG, Aust JB, Moss SE: Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: A Central Oncology Group Study. Surgery 86: 550–555, 1979.PubMedGoogle Scholar
- 15.Grage TB, Shingleton WW, Jubert AV, Elias EG, Aust JB, Moss SE: Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Front Gastrointest Res 5: 116–129, 1979.PubMedGoogle Scholar
- 17.Kemeny N, Daly JM, Oderman P, Schike M: Hepatic infusion chemotherapy for metastatic colorectal carcinoma, results and complications (Abstract). Proc Am Soc Clin Oncol 2: 123, 1983.Google Scholar
- 18.Weiss GR, Garnick MB, Osteen RT, Steele GD Jr, Wilson RE, Shade D, Kaplan W, Boxt L, Kandarpa K, Mayer R, Frei ET III: Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. 3 Clin Oncol 1: 337–344, 1983.Google Scholar
- 19.Niederhuber JE, Ensminger W, Gyves J, Thrall J, Walker S, Cozzi E: Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 53: 1336-1343,Google Scholar
- 21.Douglass HO Jr, Lavin PT, Woll J, Conroy JF, Carbone P: Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2’-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)- l(2-chloroethyl)-l-nitrosourea. A phase II-III study of the Eastern Cooperative Oncology Group (EST 4273). Cancer 42: 2538–2545, 1978.PubMedCrossRefGoogle Scholar
- 23.Borgelt BB, Gelber R, Brady LW, Griffin T, Hendrickson FR: The palliation of hepatic metastases: Results of the Radiation Therapy Oncology Group Pilot Study. Int J Radiat Oncol Biol Phys 7: 387–391, 1981.Google Scholar
- 24.Barone RM, Byfield JE, Goldfarb PB, Frankel S, Ginn C, Greer S: Intraarterial chemotherapy using an implantable infusion pump and liver irradiation for the treatment of hepatic metastases. Cancer 30: 830–862, 1982.Google Scholar
- 25.Logan S, Meier S, Ramming K, Morton D, Longmire W: Hepatic resection of metastatic colorectal carcinoma. Arch Surg 117: 23–28, 1982.Google Scholar
- 28.Flanagan K Jr, Foster JH: Hepatic resection for metastatic cancer. Am J Surg 113: 331–337, 1967.Google Scholar
- 33.Engelman L, Frame JW, Jennrick RI: BMDP Biomedical Computer Programs, P- series. In: Dixon WJ, Brown MB (eds). Publications in Automatic Computation. University of California Press, Los Angeles 1979, pp 880.Google Scholar
- 37.Starzl TE, Koep LJ, Weil R, Lilly JR, Putnam CW, Aldreter JA: Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet 130: 208–213, 1980.Google Scholar
- 38.Steele G, Osteen RT, Wilson RE, Brooks DC, Mayer RJ, Zamcheck N, Ravikumar TS: Patterns of failure after surgical cure of large liver tumors: A change in the proxinnate cause of death and a need for effective systemic adjuvant therapy. Am J Surg W: 554–559, 1984.Google Scholar